Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2286538 | 0.87 | AAK1 (0.33) | TRPA1PTPN1AAK1S1PR3ALDH1A1 | |
| SCHEMBL1712057 | 0.86 | PTGS2 (0.38) | ROCK2ROCK1SCN9AALDH1A1POLB | |
| SCHEMBL2289667 | 0.85 | SCN9A (0.34) | SCN9A | |
| SCHEMBL2292775 | 0.82 | SCN9A (0.36) | SCN9AKDM4E | |
| SCHEMBL1712460 | 0.81 | TRPA1 (0.36) | ROCK2ROCK1TRPA1PTPN1AAK1 | |
| SCHEMBL1712457 | 0.81 | TRPA1 (0.36) | ROCK2ROCK1TRPA1PTPN1AAK1 | |
| SCHEMBL2291901 | 0.79 | TRPA1 (0.36) | ROCK2ROCK1TRPA1AAK1SCN9A | |
| SCHEMBL15707645 | 0.79 | KCNH2 (0.40) | — | |
| SCHEMBL2287233 | 0.78 | SCN9A (0.34) | AAK1SCN9AALDH1A1NPSR1KDM4E | |
| SCHEMBL17446557 | 0.75 | CTSS (0.48) | ROCK2ROCK1SCN9AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618092-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-31 | — | — | US | disclosed |
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | HRH3, OXA1L, HRH1 | ROCK2 4034/4885ROCK1 3559/4885TRPA1 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.